Specifically, Komurov et al. reported that lapatinib treatment of ErbB2-positive SKBR3 breast cancer cells induced glucose deprivation, suggesting a blockage of glucose-dependent EGFR/HER2 signaling [41]. The gene discussed is EGFR; the disease is breast cancer.